|  |  |  |
| --- | --- | --- |
|  | United Nations | ST/SG/AC.10/C.4/2023/9 |
| _unlogo | **Secretariat** | Distr.: General19 September 2023Original: English |

**Committee of Experts on the Transport of Dangerous Goods
and on the Globally Harmonized System of Classification
and Labelling of Chemicals**

**Sub-Committee of Experts on the Globally Harmonized
System of Classification and Labelling of Chemicals**

**Forty-fifth session**

Geneva, 6-8 December 2023

Item 2 (i) of the provisional agenda

**Work on the Globally Harmonized System of Classification and
Labelling of Chemicals: Improvement of annexes 1 to 3 and
further rationalization of precautionary statements**

 Proposed amendments to precautionary statements in annex 3 in relation to acute toxicity and specific target organ toxicity hazard classes

Transmitted by the expert from the United Kingdom on behalf of the informal working group on improving annexes 1, 2 and 3 of the GHS[[1]](#footnote-2)\*

 I. Background

1. In line with its mandate for the 2023-2024 biennium the informal working group has taken forward work under its focus area (a): “to develop proposals to rationalise and improve the comprehensibility of hazard and precautionary statements for users, while taking into account usability for labelling practitioners.”

2. This document, together with informal document INF.3, presents the outcome of work under the first issue of item 2 in the group’s workplan for the 2023-2024 biennium[[2]](#footnote-3) to review the precautionary statements in the tables of annex 3 in relation to acute toxicity hazard categories and identify where potential improvements could be made, as detailed in paragraphs 3 to 29 and 37 to 39 below. During the review, the group also identified that a couple of related amendments were also necessary to the specific target organ toxicity hazard classes as detailed in paragraphs 31 to 35 below.

 II. Discussion

 A. Acute toxicity, inhalation, category 3: P260, P261 and P284

3. Although they present varying degrees of hazard, acute toxicity, categories 1, 2 and 3, are all considered to be of relatively high seriousness and high urgency for obtaining medical treatment, and as such categories 1, 2 and 3 of each respective acute toxicity hazard class normally receive similar precautionary statements [[3]](#footnote-4). However, a review of precautionary statements that apply to the acute toxicity inhalation hazard class identified two preventative precautionary statements that have acute toxicity inhalation, categories 1 and 2, allocated to them, but not acute toxicity, inhalation, category 3. These precautionary statements are:

(a) P260 **“Do not breathe dust/fume/gas/mist/vapours/spray.”** with the conditions for use:

“Manufacturer/supplier or the competent authority to specify applicable physical state(s).”

(b) P284 “**In case of inadequate ventilation wear respiratory protection.**”

4. The informal working group considered that acute toxicity, inhalation category 3 should also be included under these precautionary statements and be deleted from beneath P261 **“Avoid breathing dust/fume/gas/mist/vapours/spray.”**.

5. Although the precautionary statements for P260 and P261 are very similar, the group considered that the statement in P260 would convey the stronger instruction (i.e., “Do not breathe…” (in P260) rather than “Avoid...” (in P261)) that is necessary given the seriousness and high hazard of acute toxicity, inhalation, category 3 substances and mixtures. In addition, this proposed amendment would also provide greater consistency with the application of precautionary statements that are applied for categories 1 and 2 of this hazard class.

6. These proposed changes are listed in section III (paragraphs 41 to 43) and section IV of this document, and provided in full in the accompanying informal document INF.3.

 B. Acute toxicity, dermal and inhalation, category 5: P340; and P352

7. Within informal document INF.6 (forty-fourth session, paragraphs 9 to 12) the group had noted that the response combination precautionary statements for both acute toxicity dermal and inhalation category 5 required further consideration. Respectively these are:

P302+P317 “IF ON SKIN: Get medical help.”

P304+P317 “IF INHALED: **Get medical help.”**

8. Currently, the only response precautionary statement for someone who has inhaled a chemical classified as acute toxicity inhalation category 5 is to “Get medical help”.

9. Following further deliberation, the group considered that the initial action to help a person who had inhaled a chemical classified as acute toxicity inhalation category 5 should be to first remove them to fresh/clean air and then get medical help. Consequently, the group agreed that this hazard class and category should be placed under P340 (“**Remove person to fresh air and keep comfortable for breathing**.”), together with amendment of the current combination statement from: P304+P317 (**“IF INHALED: Get medical help.”**) to: P304+P340 (“IF INHALED: **Remove person to fresh air and keep comfortable for breathing.**”), as proposed in section III (paragraphs 48, 52 and 53).

10. Similarly, the group also considered that the initial action be to help a person exposed to a chemical classified as acute toxicity dermal category 5 on the skin should be to first wash it off with plenty of water and then get medical help. Consequently, the group agreed that this hazard class and category should be placed under P352 (“Wash with plenty of water/...”), together with amendment of the current combination statement from: P302+P317 (**“IF ON SKIN: Get medical help.”**) to: P302+P352 (“IF ON SKIN: Wash with plenty of water/...”), as proposed in section III (paragraphs 49 to 51).

**C. Acute toxicity, inhalation, category 4: P501**

11. The group also noted that acute toxicity, oral and dermal, category 4 are both listed under P501 “**Dispose of contents/container to…**” whereas acute toxicity, inhalation, category 4 appears to have been omitted. Given that acute toxicity, inhalation, category 4 substances and mixtures, and the containers within which they have been stored, also need to be disposed of appropriately, the group considered that acute toxicity, inhalation, category 4 should also be included under P501 with the existing conditions for use that is provided for all hazard classes under P501, as proposed in section III (paragraph 54).

12. In addition, the informal working group noted that two identical conditions for use entries are provided in column 5 for P501. As this is a minor formatting issue, rather than a proposed amendment, the group raised the issue with the secretariat who will ensure that this issue is corrected in the eleventh revision edition of the GHS.

 D. P320 “Specific treatment is urgent (see ... on this label)” and P321 “Specific treatment (see ... on this label)”

 1. Acute toxicity, inhalation, category 3

13. As detailed in paragraph 3 above, acute toxicity category 3 hazard classes normally receive similar precautionary statements as have been allocated for categories 1 and 2 for their respective hazard classes.

14. However, the informal working group noted that acute toxicity, inhalation, category 3 had been allocated to P321 “**Specific treatment (see ... on this label).**”, whereas categories 1 and 2 for this hazard class are listed beneath P320 “**Specific treatment is urgent (see ... on this label).**”.

15. Consequently, given that categories 1, 2 and 3 all require urgent treatment to be obtained, the group considered that acute toxicity, inhalation category 3 should also be included under P320 and be deleted from beneath P321, as proposed in section III (paragraphs 44 and 45).

 2. Acute toxicity, oral and dermal, categories 1, 2 and 3

16. Given that acute toxicity, oral, dermal and inhalation categories 1, 2 and 3 are all considered to be of high seriousness and high urgency for obtaining specific treatment (as detailed in paragraph 3 above), the group noted an inconsistency in relation to acute toxicity, oral and dermal, categories 1, 2 and 3 which are currently allocated to beneath P321.

17. The group considered that in view of the high urgency of obtaining specific treatment following exposure to chemicals classified as acute toxicity, oral and dermal, categories 1, 2 and 3, it would be more appropriate to list them beneath P320, rather than P321, which would also be more consistent with the allocation for the acute toxicity inhalation hazard categories 1, 2 and 3.

18. Hence the informal working group propose that acute toxicity, oral and dermal, categories 1, 2 and 3 should be included under P320 and deleted from beneath P321, as detailed in section III (paragraphs 44 and 45).

 3. Acute toxicity, oral and inhalation, category 4

19. In addition to retaining acute toxicity dermal category 4 beneath P321, given that acute toxicity, oral, dermal and inhalation, category 4 are all considered to present different hazards but are all of relatively low seriousness and high urgency for obtaining medical treatment, normally they receive similar precautionary statements 2.

20. Consequently, for greater consistency and to ensure that details regarding the necessary specific treatment are provided for all acute toxicity category 4 hazard classes, the informal working group propose that acute toxicity, oral and inhalation, category 4 should also be included beneath P321, as detailed in section III (paragraph 45).

 4. Amendments to the text of the precautionary statements and conditions for use

21. During the review, the informal working group continued its consideration of P320 and P321 in relation to the reference to the use of antidotes in the current conditions for use for acute toxicity, inhalation, categories 1 and 2 (in P320) and for acute toxicity, oral, categories 1, 2 and 3 (in P321).

22. Concerns had previously been raised regarding the appropriateness of the reference given that some jurisdictions do not routinely recommend the use of antidotes due to variety of issues including the availability of trained persons to administer the treatment and in-date medical treatment (e.g., epi-pens, inhalers) on site; storage issues; potential consequences of incorrect administration to the exposed person; target audience; and potential legal issues.

23. However, during the discussions the group learned that some jurisdictions do include reference for a small number of substances and mixtures. Although consideration was made regarding whether or not to delete P320, the group concluded that it would be appropriate to retain this statement as it expresses the urgency of obtaining treatment, and that it is important to note in the conditions of use that such treatments should be simple and easily administered, without concern for potential negative consequence of incorrect administration.

24. In addition, the group took the opportunity to propose the replacement of the dots (“…”) with the word: “**information**” in the statements for P320 and P321 as currently it is frequently found that the dots are not replaced by appropriate wording and they appear on labels, creating potential confusion and clutter through the use of irrelevant text.

25. Further, to help address the concerns raised in paragraph 22 regarding the use of antidotes, and to ensure that the appropriate information is provided on both the label and the safety data sheet, the group also propose amendments to both the P320 and P321 precautionary statements and their respective conditions for use to address these issues (see paragraphs 44 and 45). In addition, the group also propose two new precautionary statements (see section F below), that are complementary to P320 and P321, to ensure that users have the detailed information needed for training and administration of more complicated treatments.

26. The informal working group acknowledged the perennial issue of competing space on labels and considered that additional detail which may be too lengthy to provide on the label would need to be provided on the safety data sheet. In effect, a reference or “sign post” would still need to be provided on the label directing users to the safety data sheet for the more detailed information.

27. The informal working group also considered whether or not the same conditions for use could be used for all of the listed hazard classes and categories listed under P321.

28. In view of the proposed amended wording for P321 and the conditions for use for the acute toxicity oral entry under P321 would both refer to information being provided on the label and safety data sheet, and that the proposed amended conditions for use for this hazard category would refer to “..***administration of an antidote or other specific treatment.***.”, the group considered that the term “**specific treatment**” would also encompass other treatments (e.g. specific cleansing agents or measures), not just medical treatments, that may be relevant. Consequently, the group considered that the same proposed conditions for use could be applied for all the hazard classes and categories listed under P321, which would greatly simplify the current column 5 entries for P321.

29. In addition, the proposed amended conditions for use for P321 indicate that this statement may be omitted if P320 is provided on the label. This is because if both P320 and P321 were provided on the label for those substances or mixtures that have multiple classifications and listed under both these precautionary statements, there would be a large amount of duplication and in those cases, it would be the precautionary statement (i.e., with the higher urgency) from the higher hazard that would be applied. For example, if a substance was classified as both acute toxicity, inhalation, category 1 (listed under P320) and skin corrosion, category 1B (listed under P321), under the proposed amendments then only P320 would be applied.

30. The proposed changes to P320 and P321 and their respective conditions for use are provided in section III (paragraphs 44 to 45) and section IV (“Proposed amendments to the matrix tables in annex 3, section 3”) of this document and provided in full in the accompanying informal document INF.3.

E. Specific target organ toxicity, single exposure (STOT SE), category 2 and specific target organ toxicity, repeated exposure (STOT RE), category 2: P260 and P261:

31. The guidance value ranges for specific target organ toxicity, single exposure category 1 are aligned with the acute toxicity estimate values and criteria for acute toxicity categories 1, 2 and 3, while the guidance value ranges for STOT SE category 2 are aligned with the acute toxicity estimate values and criteria for acute toxicity category 4. Hence an inconsistency was identified by the group between these hazard classes and categories.

32. Currently, STOT SE category 2 and STOT RE category 2 are listed under P260 (“Do not breathe…”) when the more appropriate instruction should be to: “Avoid breathing”, as applied to acute toxicity, inhalation, category 4 listed under P261.

33. The group initially considered whether or not acute toxicity, inhalation category 4 should be move from P261 to P260 given that STOT SE and RE hazard classes were not considered to be technically within the remit of the current work item on acute toxicity issues. However, due to the close link between the estimate values and criteria for STOT SE, category 2, and acute toxicity, category 4, the group concluded that it would be more appropriate to move STOT SE, category 2, from under P260 and place it under P261.

34. In addition, to avoid any inconsistency between the application of P260 and P261 to STOT SE, category 2, and STOT RE, category 2, the group also propose to move STOT RE, category 2, from under P260 and place it under P261, together with the same conditions for use that currently applies to theses hazard classes and categories under P260 (i.e. “**Manufacturer/supplier or the competent authority to specify applicable physical state(s).**”).

35. Further, given that the words “dust/fume/gas/vapour/spray” are more accurately described as “**physical states”** rather than “**conditions”**, and in line with the change to the conditions for use that was adopted for P260 in December 2022 (see document ST/SG/AC.10/C.4/2022/16, paragraph 8 (b) (ii to iv)) for a number of health hazard classes, the group considered that it would be appropriate to amend the conditions for use for all the health hazard classes currently listed under P261. This would ensure greater alignment between the conditions for use provided for in P260 and P261.

36. These proposed changes are listed in section III (paragraph 41 and 42) and section IV of this document and provided in full in the accompanying informal document INF.3.

 F. Proposed new precautionary statements: P322 and P323

37. The group also propose to introduce two new precautionary statements “P322” and “P323” into Table A3.2.3, that are similar to P320 and P321, but which refer to information being provided on the safety data sheet. The proposed new statements read as follows:

* P322 “**Specific treatment is urgent (see information on the safety data sheet).**”
* P323 “**Specific treatment (see information on the safety data sheet).**”

38. The proposed conditions for use for P322 and P323 are also very similar to each other, each referring to additional detailed instructions and any treatment training requirements being provided on the safety data sheet for the specific substance or mixture. This enables detailed information to be provided on more complex or multi-stage treatments, including details on any additional materials or training that may be necessary for the treatment of the exposed person. The group considered that this would ensure that the manufacturer/supplier would provide the necessary detailed information for more complicated treatments that might be omitted/overlooked if only limited information were provided on the label. The information provided on the safety data sheet should be of sufficient detail to minimize the potential negative consequences of incorrect administration of an antidote or special treatment.

39. The conditions for use for P322 and P323 also provide complementary statements to those provided for P320 and P321. For the same reasoning as detailed in paragraph 29 above, the conditions for use indicate that P322 may be omitted if P320 is provided on the label, and similarly that P323 may be omitted if P321 or P322 is provided on the label.

40. The proposed new precautionary statements, conditions for use and hazard class categories are listed in section III (paragraphs 46 to 47) and section IV of this document and provided in full in the accompanying informal document INF.3.

 III. Proposed amendments to annex 3, section 2

 Table A3.2.2

 P260, column (4)

41. For “Acute toxicity, inhalation (chapter 3.1)”: Insert “, 3” after “1, 2”.

For “Specific target organ toxicity, single exposure (chapter 3.8)” and “Specific target organ toxicity, repeated exposure (chapter 3.9)”: Delete: “, 2”.

 P261

42. For “Acute toxicity, inhalation (chapter 3.1)”, column (4): delete “3,”.

 Insert the following new rows below the entry for “Skin sensitization”:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **(1)** | **(2)** | **(3)** | **(4)** | **(5)** |
|  |  | Specific target organ toxicity, single exposure (chapter 3.8) | 2 |  |
| Specific target organ toxicity, repeated exposure (chapter 3.9) | 2 |

In column (5), at the end of the current condition for use (applicable to all entries), replace “applicable conditions” with “applicable physical state(s).”

 P284, column (4)

43. For “Acute toxicity, inhalation (chapter 3.1)”, insert “, 3” after “1, 2”.

 Table A3.2.3

 P320

44. In column (2), replace “**(see … on this label)**” with “**(see information on this label and safety data sheet)**”.

Insert the following rows before the existing entry for “Acute toxicity, inhalation (chapter 3.1)”:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **(1)** | **(2)** | **(3)** | **(4)** | **(5)** |
|  |  | Acute toxicity, oral (chapter 3.1) | 1, 2, 3 |  |
|  |  | Acute toxicity, dermal (chapter 3.1) | 1, 2, 3 |

For “Acute toxicity, inhalation (chapter 3.1)”, insert “, 3” after “1, 2”.

In column (5), amend the current condition for use (applicable to all entries) to read as follows:

“- if immediate measures that can be easily applied, such as the administration of antidote or other specific treatment are required. These measures must be specified on the label and safety data sheet, recognizing additional detailed instructions, including any training requirements, should be provided on the safety data sheet, if appropriate. ”

 P321

45. In column (2) replace “**(see … on this label)**” with “**(see information on this label and safety data sheet)**”.

In column (4):

* For “Acute toxicity, oral (chapter 3.1)”, replace “1, 2, 3” with “4”.
* For “Acute toxicity, dermal (chapter 3.1)” , delete “1, 2, 3” .
* For “Acute toxicity, inhalation (chapter 3.1)” replace “ 3” with “4”.

In column (5), replace all conditions for use with the following (applicable to all entries):

“- if immediate measures that can be easily applied, such as the administration of antidote or other specific treatment are required. These measures must be specified on the label and safety data sheet, recognizing additional detailed instructions, including any training requirements, should be provided on the safety data sheet, if appropriate.

- may be omitted if P320 is given on the label.”

 P322 (new)

46. Insert the following new precautionary statement entry after P321:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **(1)** | **(2)** | **(3)** | **(4)** | **(5)** |
| P322 | **Specific treatment is urgent (see information on the safety data sheet).** | Acute toxicity, oral (chapter 3.1) | 1, 2, 3 | Manufacturer/supplier to reference on the safety data sheet detailed instructions, including any training requirements, to administer an antidote or other specific treatment.- may be omitted if P320 is given on the label. |
| Acute toxicity, dermal (chapter 3.1) | 1, 2, 3 |
| Acute toxicity, inhalation (chapter 3.1) | 1, 2, 3 |

 P323 (new)

47. Insert the following new precautionary statement entry after the new P322:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **(1)** | **(2)** | **(3)** | **(4)** | **(5)** |
| P323 | Specific treatment (see **information on the safety data sheet).** | Acute toxicity, oral (chapter 3.1) | 4 | Manufacturer/supplier to reference on the safety data sheet detailed instructions, including any training requirements, to administer an antidote or other specific treatment.- may be omitted if P321 or P322 is given on the label. |
| Acute toxicity, dermal (chapter 3.1) | 4 |
| Acute toxicity, inhalation (chapter 3.1) | 4 |
| Skin corrosion (chapter 3.2) | 1, 1A, 1B, 1C |
| Skin irritation (chapter 3.2) | 2 |
| Skin sensitization (chapter 3.4) | 1, 1A, 1B |
| Specific target organ toxicity, single exposure (chapter 3.8) | 1 |

 P340, column (4)

48. For “Acute toxicity, inhalation (chapter 3.1)”, insert “, 5” after “1, 2, 3, 4”.

 P352, column (4)

49. For “Acute toxicity, dermal (chapter 3.1)”, insert “, 5” after “1, 2, 3, 4”.

 P302+P317, column (2)

50. Replace current text with “*[Deleted]*” and delete the text under columns (3) and (4).

 P302+P352, column (4)

51. For “Acute toxicity, dermal (chapter 3.1)”, insert “, 5” after “1, 2, 3, 4”.

 P304+P317, column (2)

52. Replace current text with “*[Deleted]*” and delete the text under columns (3) and (4).

 P304+P340, column (4)

53. For “Acute toxicity, inhalation (chapter 3.1)”, insert “, 5” after “1, 2, 3, 4”.

**Table A3.2.5**

 P501

54. In column 4, for “Acute toxicity, inhalation (chapter 3.1)”, insert “, 4” after: “1, 2, 3”.

 IV. Proposed amendments to the matrix tables in annex 3, section 3

 Table for “Acute toxicity, oral (chapter 3.1)” hazard categories 1, 2, 3

55. Column “Response”, delete the P321 entry, and insert the following P320 and P322 entries (current entries for P301+P316 and P330 remain unchanged):

“P320

**Specific treatment is urgent (see information on this label and safety data sheet).**

- if immediate measures that can be easily applied, such as the administration of antidote or other specific treatment, are required. These measures must be specified on the label and safety data sheet, recognizing additional detailed instructions, including any training requirements, should be provided on the safety data sheet, if appropriate.

P322

**Specific treatment is urgent (see information on the safety data sheet).**

Manufacturer/supplier to reference on the safety data sheet detailed instructions, including any training requirements, to administer an antidote or provide other specific treatment.

- may be omitted if P320 is given on the label.”

 Table for “Acute toxicity, oral (chapter 3.1)” hazard category 4

56. Column “Response”, insert the following P321 and P323 entries (current entries for P301+P317 and P330 remain unchanged):

“P321

Specific treatment (see **information** on this label **and safety data sheet**).

- if immediate measures that can be easily applied, such as the administration of antidote or other specific treatment, are required. These measures must be specified on the label and safety data sheet, recognizing additional detailed instructions, including any training requirements, should be provided on the safety data sheet, if appropriate.

- may be omitted if P320 is given on the label.

P323

Specific treatment (see **information on the safety data sheet).**

Manufacturer/supplier to reference on the safety data sheet detailed instructions, including any training requirements, to administer an antidote or other specific treatment.
- may be omitted if P321 or P322 is given on the label.”

Tables for “Acute toxicity, dermal (chapter 3.1)” hazard categories 1, 2 and 3

57. Delete the current table for category 3. In the current table for categories 1 and 2, insert a row for category 3 under the existing row for category 2 as follows:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Hazard category** | **Symbol** |  | **Signal word** | **Hazard statement** |
| 3 | Skull and crossbones | Danger | H331 | Toxic in contact with skin |

 Column “Response”, delete the P321 entry, and insert the following P320 and P322 entries (current entries for P302+P352, P316 and P361+P364 remain unchanged):

“P320

**Specific treatment is urgent (see information on this label and safety data sheet).**

- if immediate measures that can be easily applied, such as the administration of antidote or other specific treatment, are required. These measures must be specified on the label and safety data sheet, recognizing additional detailed instructions, including any training requirements, should be provided on the safety data sheet, if appropriate.

P322

**Specific treatment is urgent (see information on the safety data sheet).**

Manufacturer/supplier to reference on the safety data sheet detailed instructions, including any training requirements, to administer an antidote or provide other specific treatment.

- may be omitted if P320 is given on the label.”

 Table for “Acute toxicity, dermal (chapter 3.1)” hazard category 4

58. Column “Response”, replace P321 and insert the new P323 entry, to read as follows (current P302+P352, P317 and P362+P364 remain unchanged):

“P321

Specific treatment (see **information** on this label and safety data sheet).

- if immediate measures that can be easily applied, such as the administration of antidote or other specific treatment, are required. These measures must be specified on the label and safety data sheet, recognizing additional detailed instructions, including any training requirements, should be provided on the safety data sheet, if appropriate.

- may be omitted if P320 is given on the label*.*

P323

Specific treatment (see **information on the safety data sheet).**

Manufacturer/supplier to reference on the safety data sheet detailed instructions, including any training requirements, to administer an antidote or other specific treatment.

- may be omitted if P321 or P322 is given on the label”.

 Table for “Acute toxicity, dermal (chapter 3.1)” hazard category 5

59.Column “Response”, amend to read:

“P317 **Get medical help.**

P302+P352 **IF ON SKIN: Wash with plenty of water/…**

…Manufacturer/supplier or the competent authority may specify a cleansing agent if appropriate, or may recommend an alternative agent in exceptional cases if water is clearly inappropriate.”

Tables for “Acute toxicity, inhalation (chapter 3.1)” hazard categories 1, 2, 3

60. Delete the current table for category 3. In the current table for categories 1 and 2, insert a row for category 3 under the existing row for category 2 as follows:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Hazard category** | **Symbol** |  | **Signal word** | **Hazard statement** |
| 3 | Skull and crossbones | Danger | H331 | Toxic if inhaled |

Column “Response”, delete the P321 entry, amend P320 and insert a new P322 entry as follows (current entries for P304+P340 and P316 remain unchanged):

“P320

**Specific treatment is urgent (see information on this label and safety data sheet).**

*- if immediate measures that can be easily applied, such as the administration of antidote or other specific treatment, are required. These measures must be specified on the label and safety data sheet, recognizing additional detailed instructions, including any training requirements, should be provided on the safety data sheet, if appropriate.*

P322

**Specific treatment is urgent (see information on the safety data sheet).**

Manufacturer/supplier to reference on the safety data sheet detailed instructions, including any training requirements, to administer an antidote or other specific treatment.

*- may be omitted if P320 is given on the label.”*

 Table for “Acute toxicity, inhalation (chapter 3.1)” hazard category 4

61. Column “Prevention”, for the P261 entry replace “…. to specify applicable conditions.” with “… to specify applicable physical state(s).” (current entry P271 remains unchanged).

Column “Response”, insert new P321 and P323 entries to read as follows (current entries for P304+P340 and P317 remain unchanged):

“P321

Specific treatment (see **information** on this label and safety data sheet).

- if immediate measures that can be easily applied, such as the administration of antidote or other specific treatment, are required. These measures must be specified on the label and safety data sheet, recognizing additional detailed instructions, including any training requirements, should be provided on the safety data sheet, if appropriate.

- may be omitted if P320 is given on the label*.*

P323

Specific treatment (see **information on the safety data sheet).**

Manufacturer/supplier to reference on the safety data sheet detailed instructions, including any training requirements, to administer an antidote or other specific treatment.

- may be omitted if P321 or P322 is given on the label.”

62. Column “Disposal”, insert a new entry for P501, to read as follows:

“P501

**Dispose of contents/container to...**

... in accordance with local/regional/national/international regulations (to be specified).

Manufacturer/supplier or the competent authority to specify whether disposal requirements apply to contents, container or both.”

 Table for Acute toxicity, inhalation (chapter 3.1)” hazard category 5

63. Column “Response”, amend to read:

“P317

**Get medical help.**

P304+P340

**IF INHALED: Remove person to fresh air and keep comfortable for breathing.”**

 Table for “Skin corrosion/irritation (chapter 3.2)” hazard categories 1, 1A, 1B, 1C

64. Column “Response”, replace P321 and insert a new P323 entry, to read as follows (current entries for P301+P330+P331, P302+P361+P354, P363, P304+P340, P316 and P305+P354+P338 remain unchanged):

“P321

Specific treatment (see **information** on this label and safety data sheet).

- if immediate measures that can be easily applied, such as the administration of antidote or other specific treatment, are required. These measures must be specified on the label and safety data sheet, recognizing additional detailed instructions, including any training requirements, should be provided on the safety data sheet, if appropriate.

- may be omitted if P320 is given on the label*.*

P323

Specific treatment (see **information on the safety data sheet).**

Manufacturer/supplier to reference on the safety data sheet detailed instructions, including any training requirements, to administer an antidote or other specific treatment.

- may be omitted if P321 or P322 is given on the label.”

 Table for “Skin corrosion/irritation (chapter 3.2)” hazard category 2

65. Column “Response”, amend P321 and insert a new P323 entry to read as follows (current entries P302+P352, P332+P317 and P362+P364 remain unchanged):

“P321

Specific treatment (see **information** on this label and safety data sheet).

- if immediate measures that can be easily applied, such as the administration of antidote or other specific treatment, are required. These measures must be specified on the label and safety data sheet, recognizing additional detailed instructions, including any training requirements, should be provided on the safety data sheet, if appropriate.

- may be omitted if P320 is given on the label*.*

P323

Specific treatment (see **information on the safety data sheet).**

Manufacturer/supplier to reference on the safety data sheet detailed instructions, including any training requirements, to administer an antidote or other specific treatment.

- may be omitted if P321 or P322 is given on the label.”.

 Table for “Skin sensitization (chapter 3.4)” hazard categories 1, 1A, 1B

66. Column “Prevention”, for the P261 entry replace “…. to specify applicable conditions.” with “… to specify applicable physical state(s).” (current entries P272 and P280 remain unchanged).

Column “Response”, amend P321 and insert a new P323 entry to read as follows (current entries P302+P352, P333+P317 and P362+P364 remain unchanged):

“P321

Specific treatment (see **information** on this label and safety data sheet).

- if immediate measures that can be easily applied, such as the administration of antidote or other specific treatment, are required. These measures must be specified on the label and safety data sheet, recognizing additional detailed instructions, including any training requirements, should be provided on the safety data sheet, if appropriate.

- may be omitted if P320 is given on the label*.*

P323

Specific treatment (see **information on the safety data sheet).**

Manufacturer/supplier to reference on the safety data sheet detailed instructions, including any training requirements, to administer an antidote or other specific treatment.

- may be omitted if P321 or P322 is given on the label.”.

 Table for “Specific target organ toxicity (single exposure) (chapter 3.8)” hazard category 1

67. Column “Response”, amend P321 and insert a new P323 entry, to read as follows (current entry for P308+P316 remains unchanged):

“P321

Specific treatment (see **information** on this label and safety data sheet).

- if immediate measures that can be easily applied, such as the administration of antidote or other specific treatment, are required. These measures must be specified on the label and safety data sheet, recognizing additional detailed instructions, including any training requirements, should be provided on the safety data sheet, if appropriate.

- may be omitted if P320 is given on the label*.*

P323

Specific treatment (see **information on the safety data sheet).**

Manufacturer/supplier to reference on the safety data sheet detailed instructions, including any training requirements, to administer an antidote or other specific treatment.

- may be omitted if P321 or P322 is given on the label.”.

Table for “Specific target organ toxicity (single exposure) (chapter 3.8)” hazard category 2

68. Column “Prevention”, delete the P260 entry and insert a P261 entry to read as follows (current entries for P264 and P270 remain unchanged):

“P261

**Avoid breathing dust/fume/gas/mist/ vapours/spray.**

*– may be omitted if P260 is given on the label*

Manufacturer/supplier or the competent authority to specify applicable physical state(s).*”*

Table for “Specific target organ toxicity (repeated exposure) (chapter 3.8)” hazard category 2

69. Column “Prevention”, delete the P260 entry and insert a new P261 entry to read as follows:

“P261

**Avoid breathing dust/fume/gas/mist/ vapours/spray.**

*– may be omitted if P260 is given on the label*

Manufacturer/supplier or the competent authority to specify applicable physical state(s).*”*

Table for “Specific target organ toxicity (single exposure) (chapter 3.8)” hazard category 3

70. Column “Prevention”, for P261 replace “…. to specify applicable conditions.” with “… to specify applicable physical state(s).” (current entry P271 remains unchanged).

Action requested

71. The Sub-Committee is invited to agree the proposed amendments to sections 2 and 3 of Annex 3 of the GHS as set out in this document in the following paragraphs and shown in full in informal document INF.3:

• Section 2 proposed amendments are provided in section III, paragraphs 41 to 54.

* Section 3 proposed amendments are provided in section IV, paragraphs 55 to 70.

1. \* A/77/6 (Sect. 20), table 20.6. [↑](#footnote-ref-2)
2. See informal document INF.17, forty-third session. [↑](#footnote-ref-3)
3. See figure 1 in document ST/SG/AC.10/C.4/2018/30, thirty-sixth session. [↑](#footnote-ref-4)